ARUP Labs Chief Advocates Closer Monitoring Of Clinician Test Orders
This article was originally published in The Gray Sheet
Clinical pathologists concerned with inappropriate test orders should look to the drug industry for examples of ways to alter physician practices, ARUP Laboratories Medical Director Brian Jackson, MD, advised June 7 in an online dialogue with test providers
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.